周涵, 梁伟, 丁国华. IgA肾病伴高尿酸血症的临床意义[J]. 临床肾脏病杂志, 2024, 24(8): 681-686. DOI: 10.3969/j.issn.1671-2390.2024.08.010
    引用本文: 周涵, 梁伟, 丁国华. IgA肾病伴高尿酸血症的临床意义[J]. 临床肾脏病杂志, 2024, 24(8): 681-686. DOI: 10.3969/j.issn.1671-2390.2024.08.010
    Zhou Han, Liang Wei, Ding Guo-hua. Clinical significance of IgA nephropathy with hyperuricemia[J]. Journal of Clinical Nephrology, 2024, 24(8): 681-686. DOI: 10.3969/j.issn.1671-2390.2024.08.010
    Citation: Zhou Han, Liang Wei, Ding Guo-hua. Clinical significance of IgA nephropathy with hyperuricemia[J]. Journal of Clinical Nephrology, 2024, 24(8): 681-686. DOI: 10.3969/j.issn.1671-2390.2024.08.010

    IgA肾病伴高尿酸血症的临床意义

    Clinical significance of IgA nephropathy with hyperuricemia

    • 摘要: IgA肾病(immunoglobulin A nephropathy,IgAN)属于常见的原发性肾小球肾炎之一,也是终末期肾病(end-stage renal disease, ESRD)的主要病因之一。IgAN的治疗仍然存在挑战,干预相关的危险因素,可延缓疾病的进展。近年发现,高尿酸血症是IgAN患者常见的临床特点,也是疾病进展的危险因素之一,但高尿酸血症与IgAN病理改变及疾病进展的关系仍不明确。因此,明确高尿酸血症与IgAN的关系具有重要的临床意义。本文从高尿酸血症在IgAN中的患病率、相关的发病机制与IgAN进展的关系及治疗靶点等方面进行了较为详尽的综述。

       

      Abstract: As one of the most common primary glomerulopathies, immunoglobulin A nephropathy(IgAN) is a major cause of end-stage renal disease (ESRD). Its proper treatment has remained rather challenging. Disease progression may be delayed if associated risk factors are intervened. Hyperuricemia is a common clinical feature of IgAN and it is correlated with disease progression. However, the relationship has been elusive between hyperuricemia, pathological injury and disease progression in IgAN. This review focused upon the prevalence of hyperuricemia in IgAN, related pathogenesis and the relationship with the progression of IgAN and therapeutic targets.

       

    /

    返回文章
    返回